124 related articles for article (PubMed ID: 26778106)
1. The risk for developing cancer in Israeli ATM, BLM, and FANCC heterozygous mutation carriers.
Laitman Y; Boker-Keinan L; Berkenstadt M; Liphsitz I; Weissglas-Volkov D; Ries-Levavi L; Sarouk I; Pras E; Friedman E
Cancer Genet; 2016 Mar; 209(3):70-4. PubMed ID: 26778106
[TBL] [Abstract][Full Text] [Related]
2. Double heterozygotes among breast cancer patients analyzed for BRCA1, CHEK2, ATM, NBN/NBS1, and BLM germ-line mutations.
Sokolenko AP; Bogdanova N; Kluzniak W; Preobrazhenskaya EV; Kuligina ES; Iyevleva AG; Aleksakhina SN; Mitiushkina NV; Gorodnova TV; Bessonov AA; Togo AV; Lubiński J; Cybulski C; Jakubowska A; Dörk T; Imyanitov EN
Breast Cancer Res Treat; 2014 Jun; 145(2):553-62. PubMed ID: 24800916
[TBL] [Abstract][Full Text] [Related]
3. Exome sequencing identifies rare deleterious mutations in DNA repair genes FANCC and BLM as potential breast cancer susceptibility alleles.
Thompson ER; Doyle MA; Ryland GL; Rowley SM; Choong DY; Tothill RW; Thorne H; ; Barnes DR; Li J; Ellul J; Philip GK; Antill YC; James PA; Trainer AH; Mitchell G; Campbell IG
PLoS Genet; 2012 Sep; 8(9):e1002894. PubMed ID: 23028338
[TBL] [Abstract][Full Text] [Related]
4. Health risks for ataxia-telangiectasia mutated heterozygotes: a systematic review, meta-analysis and evidence-based guideline.
van Os NJ; Roeleveld N; Weemaes CM; Jongmans MC; Janssens GO; Taylor AM; Hoogerbrugge N; Willemsen MA
Clin Genet; 2016 Aug; 90(2):105-17. PubMed ID: 26662178
[TBL] [Abstract][Full Text] [Related]
5. Telomere length, ATM mutation status and cancer risk in Ataxia-Telangiectasia families.
Renault AL; Mebirouk N; Cavaciuti E; Le Gal D; Lecarpentier J; d'Enghien CD; Laugé A; Dondon MG; Labbé M; Lesca G; Leroux D; Gladieff L; Adenis C; Faivre L; Gilbert-Dussardier B; Lortholary A; Fricker JP; Dahan K; Bay JO; Longy M; Buecher B; Janin N; Zattara H; Berthet P; Combès A; Coupier I; ; Hall J; Stoppa-Lyonnet D; Andrieu N; Lesueur F
Carcinogenesis; 2017 Oct; 38(10):994-1003. PubMed ID: 28981872
[TBL] [Abstract][Full Text] [Related]
6. A common nonsense mutation of the BLM gene and prostate cancer risk and survival.
Antczak A; Kluźniak W; Wokołorczyk D; Kashyap A; Jakubowska A; Gronwald J; Huzarski T; Byrski T; Dębniak T; Masojć B; Górski B; Gromowski T; Nagorna A; Gołąb A; Sikorski A; Słojewski M; Gliniewicz B; Borkowski T; Borkowski A; Przybyła J; Sosnowski M; Małkiewicz B; Zdrojowy R; Sikorska-Radek P; Matych J; Wilkosz J; Różański W; Kiś J; Bar K; Domagała P; Stawicka M; Milecki P; Akbari MR; Narod SA; Lubiński J; Cybulski C; ; ; Bryniarski P; Paradysz A; Jersak K; Niemirowicz J; Słupski P; Jarzemski P; Skrzypczyk M; Dobruch J; Domagała W; Chosia M; van de Wetering T; Serrano-Fernández P; Puszyński M; Soczawa M; Switała J; Archimowicz S; Kordowski M; Zyczkowski M; Borówka A; Bagińska J; Krajka K; Szwiec M; Haus O; Janiszewska H; Stembalska A; Sąsiadek MM
Gene; 2013 Dec; 532(2):173-6. PubMed ID: 24096176
[TBL] [Abstract][Full Text] [Related]
7. Prevalence of breast and colorectal cancer in Ashkenazi Jewish carriers of Fanconi anemia and Bloom syndrome.
Baris HN; Kedar I; Halpern GJ; Shohat T; Magal N; Ludman MD; Shohat M
Isr Med Assoc J; 2007 Dec; 9(12):847-50. PubMed ID: 18210922
[TBL] [Abstract][Full Text] [Related]
8. Deleterious Germline BLM Mutations and the Risk for Early-onset Colorectal Cancer.
de Voer RM; Hahn MM; Mensenkamp AR; Hoischen A; Gilissen C; Henkes A; Spruijt L; van Zelst-Stams WA; Kets CM; Verwiel ET; Nagtegaal ID; Schackert HK; van Kessel AG; Hoogerbrugge N; Ligtenberg MJ; Kuiper RP
Sci Rep; 2015 Sep; 5():14060. PubMed ID: 26358404
[TBL] [Abstract][Full Text] [Related]
9. Colorectal and Endometrial Cancer Risk and Age at Diagnosis in BLMAsh Mutation Carriers.
Schayek H; Laitman Y; Katz LH; Pras E; Ries-Levavi L; Barak F; Friedman E
Isr Med Assoc J; 2017 Jun; 19(6):365-367. PubMed ID: 28647934
[TBL] [Abstract][Full Text] [Related]
10. Phenocopy breast cancer rates in Israeli BRCA1 BRCA2 mutation carrier families: is the risk increased in non-carriers?
Bernholtz S; Laitman Y; Kaufman B; Shimon-Paluch S; Friedman E
Breast Cancer Res Treat; 2012 Apr; 132(2):669-73. PubMed ID: 22113258
[TBL] [Abstract][Full Text] [Related]
11. Heterozygosity for the BLM(Ash) mutation and cancer risk.
Cleary SP; Zhang W; Di Nicola N; Aronson M; Aube J; Steinman A; Haddad R; Redston M; Gallinger S; Narod SA; Gryfe R
Cancer Res; 2003 Apr; 63(8):1769-71. PubMed ID: 12702560
[TBL] [Abstract][Full Text] [Related]
12. ATM mutations for surgeons.
Mansfield SA; Pilarski R; Agnese DM
Fam Cancer; 2017 Jul; 16(3):407-410. PubMed ID: 27988859
[TBL] [Abstract][Full Text] [Related]
13. Cancer in patients with ataxia-telangiectasia and in their relatives in the nordic countries.
Olsen JH; Hahnemann JM; Børresen-Dale AL; Brøndum-Nielsen K; Hammarström L; Kleinerman R; Kääriäinen H; Lönnqvist T; Sankila R; Seersholm N; Tretli S; Yuen J; Boice JD; Tucker M
J Natl Cancer Inst; 2001 Jan; 93(2):121-7. PubMed ID: 11208881
[TBL] [Abstract][Full Text] [Related]
14. Mice heterozygous for mutation in Atm, the gene involved in ataxia-telangiectasia, have heightened susceptibility to cancer.
Spring K; Ahangari F; Scott SP; Waring P; Purdie DM; Chen PC; Hourigan K; Ramsay J; McKinnon PJ; Swift M; Lavin MF
Nat Genet; 2002 Sep; 32(1):185-90. PubMed ID: 12195425
[TBL] [Abstract][Full Text] [Related]
15. FANCC Dutch founder mutation in a Mennonite family from Tamaulipas, México.
García-de Teresa B; Frias S; Molina B; Villarreal MT; Rodriguez A; Carnevale A; López-Hernández G; Vollbrechtshausen L; Olaya-Vargas A; Torres L
Mol Genet Genomic Med; 2019 Jun; 7(6):e710. PubMed ID: 31044565
[TBL] [Abstract][Full Text] [Related]
16. Nonsense mutation p.Q548X in BLM, the gene mutated in Bloom's syndrome, is associated with breast cancer in Slavic populations.
Prokofyeva D; Bogdanova N; Dubrowinskaja N; Bermisheva M; Takhirova Z; Antonenkova N; Turmanov N; Datsyuk I; Gantsev S; Christiansen H; Park-Simon TW; Hillemanns P; Khusnutdinova E; Dörk T
Breast Cancer Res Treat; 2013 Jan; 137(2):533-9. PubMed ID: 23225144
[TBL] [Abstract][Full Text] [Related]
17. Critical role of FANCC in JAK2 V617F mutant-induced resistance to DNA cross-linking drugs.
Ueda F; Sumi K; Tago K; Kasahara T; Funakoshi-Tago M
Cell Signal; 2013 Nov; 25(11):2115-24. PubMed ID: 23838005
[TBL] [Abstract][Full Text] [Related]
18. A heterozygous frameshift mutation in the Fanconi anemia C gene in familial T-ALL and secondary malignancy.
Rischewski JR; Clausen H; Leber V; Niemeyer C; Ritter J; Schindler D; Schneppenheim R
Klin Padiatr; 2000; 212(4):174-6. PubMed ID: 10994546
[TBL] [Abstract][Full Text] [Related]
19. Contribution of mutations in ATM to breast cancer development in the Czech population.
Soukupova J; Dundr P; Kleibl Z; Pohlreich P
Oncol Rep; 2008 Jun; 19(6):1505-10. PubMed ID: 18497957
[TBL] [Abstract][Full Text] [Related]
20. Cancer risk in heterozygotes for ataxia-telangiectasia.
Geoffroy-Perez B; Janin N; Ossian K; Laugé A; Croquette MF; Griscelli C; Debré M; Bressac-de-Paillerets B; Aurias A; Stoppa-Lyonnet D; Andrieu N
Int J Cancer; 2001 Jul; 93(2):288-93. PubMed ID: 11410879
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
